These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 6255896)
21. Antibody responses and protection in mice immunized with herpes simplex virus type 1 antigen immune-stimulating complex preparations. Ertürk M; Jennings R; Hockley D; Potter CW J Gen Virol; 1989 Aug; 70 ( Pt 8)():2149-55. PubMed ID: 2769234 [TBL] [Abstract][Full Text] [Related]
22. Effect of B cell suppression on primary infection and reinfection of mice with herpes simplex virus. Simmons A; Nash AA J Infect Dis; 1987 Apr; 155(4):649-54. PubMed ID: 3029240 [TBL] [Abstract][Full Text] [Related]
23. Preparation and efficacy of an inactivated subunit vaccine (NFUIBHK) against type 2 Herpes simplex virus infection. Skinner GR; Williams DR; Buchan A; Whitney J; Harding M; Bodfish K Med Microbiol Immunol; 1978 Nov; 166(1-4):119-32. PubMed ID: 214676 [TBL] [Abstract][Full Text] [Related]
24. Immune responses in mice against herpes simplex virus: mechanisms of protection against facial and ganglionic infections. Zweerink HJ; Martinez D; Lynch RJ; Stanton LW Infect Immun; 1981 Jan; 31(1):267-75. PubMed ID: 6260662 [TBL] [Abstract][Full Text] [Related]
25. Efficacy of the herpes simplex virus types 1 and 2 mutant viruses to confer protection against zosteriform spread in mice. Mercadal CM; Slaoui M; Brown SM; Rouse BT Viral Immunol; 1993; 6(1):35-42. PubMed ID: 8386516 [TBL] [Abstract][Full Text] [Related]
27. Immunogenicity of subviral herpes simplex virus preparations. I. Formation of neutralizing antibodies in different animal species after administration of herpes simplex virus solubilized antigens. Kutinová L; Slichtová V; Vonka V Arch Virol; 1979; 61(1-2):141-7. PubMed ID: 229789 [TBL] [Abstract][Full Text] [Related]
28. Latency of herpes simplex virus in absence of neutralizing antibody: model for reactivation. Sekizawa T; Openshaw H; Wohlenberg C; Notkins AL Science; 1980 Nov; 210(4473):1026-8. PubMed ID: 6254149 [TBL] [Abstract][Full Text] [Related]
29. Role of bovine mammillitis virus towards preparation of an alternative vaccine against herpes simplex virus infections of human subjects. Skinner GR; Buchan A; Durham J; Cowan M; Davies J; Brookes K; Castrucci G Vaccine; 1987 Mar; 5(1):55-9. PubMed ID: 3033927 [TBL] [Abstract][Full Text] [Related]
31. Animal studies on the efficacy of vaccination against recurrent herpes. Scriba M Med Microbiol Immunol; 1982; 171(1):33-42. PubMed ID: 6289061 [TBL] [Abstract][Full Text] [Related]
32. Comparison of effects of adjuvants on efficacy of virion envelope herpes simplex virus vaccine against labial infection of BALB/c mice. Thomson TA; Hilfenhaus J; Moser H; Morahan PS Infect Immun; 1983 Aug; 41(2):556-62. PubMed ID: 6307874 [TBL] [Abstract][Full Text] [Related]
33. Immunological memory to herpes simplex virus type 1 glycoproteins B and D in mice. Blacklaws BA; Nash AA J Gen Virol; 1990 Apr; 71 ( Pt 4)():863-71. PubMed ID: 2157799 [TBL] [Abstract][Full Text] [Related]
34. Prevention of type 2 herpes simplex virus induced cervical carcinoma in mice by prior immunization with a vaccine prepared from type 1 herpes simplex virus. Chen MH; Dong CY; Liu ZH; Skinner GR; Hartley CE Vaccine; 1983 Dec; 1(1):13-6. PubMed ID: 6099637 [TBL] [Abstract][Full Text] [Related]
35. The quest for a herpes simplex virus vaccine: background and recent developments. Hall MJ; Katrak K Vaccine; 1986 Sep; 4(3):138-50. PubMed ID: 3020819 [TBL] [Abstract][Full Text] [Related]
36. Protection against ocular and cutaneous infection with herpes simplex virus type 1 by intragastric immunization with live virus. Irie H; Shimeld C; Williams N; Hill T J Gen Virol; 1993 Jul; 74 ( Pt 7)():1357-62. PubMed ID: 8393076 [TBL] [Abstract][Full Text] [Related]
37. Prepubertal vaccination of mice against experimental infection of the genital tract with type 2 herpes simplex virus. Skinner GR; Williams DR; Moles AW; Sargent A Arch Virol; 1980; 64(4):329-38. PubMed ID: 6249243 [TBL] [Abstract][Full Text] [Related]
38. Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems. Mohamedi SA; Brewer JM; Alexander J; Heath AW; Jennings R Vaccine; 2000 Apr; 18(20):2083-94. PubMed ID: 10715522 [TBL] [Abstract][Full Text] [Related]
39. Latent HSV-1 infection in mice immunized with a zwitterionic detergent-extracted HSV-1 antigen preparation. al-Ghamdi A; Jennings R; Bentley H; Potter CW Arch Virol; 1989; 108(1-2):19-31. PubMed ID: 2556982 [TBL] [Abstract][Full Text] [Related]
40. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine. Sanchez-Pescador L; Burke RL; Ott G; Van Nest G J Immunol; 1988 Sep; 141(5):1720-7. PubMed ID: 2842401 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]